Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis Curr Fungal Infect Rep (2017) 11:67–74 DOI 10.1007/s12281-017-0281-x CURRENT MANAGEMENT OF FUNGAL INFECTIONS (M MICELI, SECTION EDITOR) Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis Carol A. Kauffman Published online: 21 June 2017 Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of this review is to assess the recommended treatment regimens for the major endemic my- Standard treatment of infection caused by the major endemic coses, histoplasmosis and blastomycosis, which occur in the mycoses that are found primarily in the Midwestern USA, Midwestern USA and to provide information about the use of blastomycosis and histoplasmosis, remains amphotericin B newer antifungal agents for these diseases. and/or azole antifungal agents. The echinocandins and Recent Findings The basic approach to treatment of histoplas- flucytosine do not have activity against the organisms causing mosis and blastomycosis outlined in the IDSA Guidelines is these infections and should not be used for treatment. Changes helpful in managing these diseases. However, changes since in treatment regimens that have been seen in the last decade these guidelines were published provide safer and better tol- include the increased use of new azole agents, specifically erated treatment regimens. Prolonged treatment with voriconazole and posaconazole, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Fungal Infection Reports Springer Journals

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

Current Fungal Infection Reports , Volume 11 (3) – Jun 21, 2017

Loading next page...
 
/lp/springer_journal/treatment-of-the-midwestern-endemic-mycoses-blastomycosis-and-HAi0uV0xdh

References (64)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Infectious Diseases; Internal Medicine; Tropical Medicine; Occupational Medicine/Industrial Medicine; Pneumology/Respiratory System
ISSN
1936-3761
eISSN
1936-377X
DOI
10.1007/s12281-017-0281-x
Publisher site
See Article on Publisher Site

Abstract

Curr Fungal Infect Rep (2017) 11:67–74 DOI 10.1007/s12281-017-0281-x CURRENT MANAGEMENT OF FUNGAL INFECTIONS (M MICELI, SECTION EDITOR) Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis Carol A. Kauffman Published online: 21 June 2017 Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of this review is to assess the recommended treatment regimens for the major endemic my- Standard treatment of infection caused by the major endemic coses, histoplasmosis and blastomycosis, which occur in the mycoses that are found primarily in the Midwestern USA, Midwestern USA and to provide information about the use of blastomycosis and histoplasmosis, remains amphotericin B newer antifungal agents for these diseases. and/or azole antifungal agents. The echinocandins and Recent Findings The basic approach to treatment of histoplas- flucytosine do not have activity against the organisms causing mosis and blastomycosis outlined in the IDSA Guidelines is these infections and should not be used for treatment. Changes helpful in managing these diseases. However, changes since in treatment regimens that have been seen in the last decade these guidelines were published provide safer and better tol- include the increased use of new azole agents, specifically erated treatment regimens. Prolonged treatment with voriconazole and posaconazole,

Journal

Current Fungal Infection ReportsSpringer Journals

Published: Jun 21, 2017

There are no references for this article.